MingMed Biotech Joins Queue of Revenue-less Drug Startups Seeking IPO Cash
It has seven drugs under development but none on the market yet. But one thing MingMed Biotech has plenty of is losses Key Takeaways: With no drug revenues and growing…
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK -
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- InSilico seeks IPO boost to get AI drugs over the line
